AbbVie (ABBV) Says Upadacitinib Met Primary and Key Efficacy Endpoints in Phase 2b/3 RA Study in Japanese Patients
April 25, 2018 8:36 AM
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2b/3 SELECT-SUNRISE clinical trial ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
